FDA
-
-
-
-
-
-
-
QIAGEN Gains U.S. Clearance of Higher-Throughput QIAstat-Dx Rise, Expanding Patient Access to Rapid Syndromic Testing
-
-
-
-
-
-
-
QIAGEN and Myriad Genetics develop distributable homologous recombination deficiency test for global research and companion diagnostics applications
-
-
-
-
-
-
-
QIAGEN receives FDA approval for companion diagnostic to Mirati Therapeutics’ KRAZATI in non-small cell lung cancer
-
-
-
-
-
-
-
QIAGEN and Denovo Biopharma Partner to Develop Companion Diagnostic Test for the Treatment of Diffuse Large B-Cell Lymphoma (DLBCL)
-
-
-
-
-
-
-
QIAGEN receives U.S. FDA emergency use authorization for rapid portable test that can analyze over 30 samples per hour for SARS-CoV-2 antigen
-
-
-
-
-
-
-
QIAGEN Launches First FDA-approved Tissue Companion Diagnostic to Identify the KRAS G12C Mutation in NSCLC Tumours and Expand Precision Medicine Options in Lung Cancer
-
-
-
-
-
-
-
Qiagen (QGEN) Granted FDA Emergency Use for NeuMoDx Multiplex Test to Quickly Identify Respiratory Viral Infection Consistent with COVID-19
-
326,823 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

